Thermo Fisher Scientific Inc. (TSX: TMO.TO) Stock Competitors & Peer Comparison

Thermo Fisher Scientific Inc. (TSX: TMO.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMO.TO stands at 359.5B. In comparison, TMO.NE has a market cap of 341B. Regarding current trading prices, TMO.TO is priced at CA$24.72 on the TSX, while TMO.NE trades at CA$24.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMO.TO currently has a P/E ratio of 34.82, whereas TMO.NE's P/E ratio is 1.81. In terms of profitability, TMO.TO's ROE is N/A, compared to TMO.NE's ROE of +0.13%. Regarding short-term risk, TMO.TO is more volatile compared to TMO.NE. This indicates higher risk in terms of short-term price fluctuations for TMO.TO.Check TMO.NE's competition here

Thermo Fisher Scientific Inc. (TSX: TMO.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMO.TO stands at 359.5B. In comparison, EDT.TO has a market cap of 284.7M. Regarding current trading prices, TMO.TO is priced at CA$24.72 on the TSX, while EDT.TO trades at CA$0.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMO.TO currently has a P/E ratio of 34.82, whereas EDT.TO's P/E ratio is -7.53. In terms of profitability, TMO.TO's ROE is N/A, compared to EDT.TO's ROE of +0.51%. Regarding short-term risk, TMO.TO is more volatile compared to EDT.TO. This indicates higher risk in terms of short-term price fluctuations for TMO.TO.Check EDT.TO's competition here

Thermo Fisher Scientific Inc. (TSX: TMO.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMO.TO stands at 359.5B. In comparison, BUX.CN has a market cap of 47.9M. Regarding current trading prices, TMO.TO is priced at CA$24.72 on the TSX, while BUX.CN trades at CA$0.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMO.TO currently has a P/E ratio of 34.82, whereas BUX.CN's P/E ratio is -24.03. In terms of profitability, TMO.TO's ROE is N/A, compared to BUX.CN's ROE of -2.51%. Regarding short-term risk, TMO.TO is more volatile compared to BUX.CN. This indicates higher risk in terms of short-term price fluctuations for TMO.TO.Check BUX.CN's competition here

Thermo Fisher Scientific Inc. (TSX: TMO.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMO.TO stands at 359.5B. In comparison, AKU.TO has a market cap of 45.2M. Regarding current trading prices, TMO.TO is priced at CA$24.72 on the TSX, while AKU.TO trades at CA$0.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMO.TO currently has a P/E ratio of 34.82, whereas AKU.TO's P/E ratio is -0.14. In terms of profitability, TMO.TO's ROE is N/A, compared to AKU.TO's ROE of -5.50%. Regarding short-term risk, TMO.TO is more volatile compared to AKU.TO. This indicates higher risk in terms of short-term price fluctuations for TMO.TO.Check AKU.TO's competition here

Thermo Fisher Scientific Inc. (TSX: TMO.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMO.TO stands at 359.5B. In comparison, IZO.CN has a market cap of 8M. Regarding current trading prices, TMO.TO is priced at CA$24.72 on the TSX, while IZO.CN trades at CA$0.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMO.TO currently has a P/E ratio of 34.82, whereas IZO.CN's P/E ratio is -3.50. In terms of profitability, TMO.TO's ROE is N/A, compared to IZO.CN's ROE of +0.40%. Regarding short-term risk, TMO.TO is less volatile compared to IZO.CN. This indicates lower risk in terms of short-term price fluctuations for TMO.TO.Check IZO.CN's competition here

Thermo Fisher Scientific Inc. (TSX: TMO.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMO.TO stands at 359.5B. In comparison, SZLS.TO has a market cap of 4.9M. Regarding current trading prices, TMO.TO is priced at CA$24.72 on the TSX, while SZLS.TO trades at CA$0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMO.TO currently has a P/E ratio of 34.82, whereas SZLS.TO's P/E ratio is -1.61. In terms of profitability, TMO.TO's ROE is N/A, compared to SZLS.TO's ROE of +4.82%. Regarding short-term risk, TMO.TO is more volatile compared to SZLS.TO. This indicates higher risk in terms of short-term price fluctuations for TMO.TO.Check SZLS.TO's competition here

Thermo Fisher Scientific Inc. (TSX: TMO.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMO.TO stands at 359.5B. In comparison, SCRN.CN has a market cap of 1.5M. Regarding current trading prices, TMO.TO is priced at CA$24.72 on the TSX, while SCRN.CN trades at CA$0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMO.TO currently has a P/E ratio of 34.82, whereas SCRN.CN's P/E ratio is -0.25. In terms of profitability, TMO.TO's ROE is N/A, compared to SCRN.CN's ROE of -14.30%. Regarding short-term risk, TMO.TO is more volatile compared to SCRN.CN. This indicates higher risk in terms of short-term price fluctuations for TMO.TO.Check SCRN.CN's competition here

Thermo Fisher Scientific Inc. (TSX: TMO.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMO.TO stands at 359.5B. In comparison, MEDV.NE has a market cap of 810.6K. Regarding current trading prices, TMO.TO is priced at CA$24.72 on the TSX, while MEDV.NE trades at CA$0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMO.TO currently has a P/E ratio of 34.82, whereas MEDV.NE's P/E ratio is -0.09. In terms of profitability, TMO.TO's ROE is N/A, compared to MEDV.NE's ROE of +2.13%. Regarding short-term risk, TMO.TO is less volatile compared to MEDV.NE. This indicates lower risk in terms of short-term price fluctuations for TMO.TO.Check MEDV.NE's competition here